Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes

S.Y. Loh, P. Mistry, L.R. Kelland, G. Abel & K.R. Harrap

Drug Development Section, The Institute of Cancer Research, Belmont, Sutton, Surrey SM2 5NG, UK.

Summary

Acquired resistance to cisplatin (cis-diaminedichloroplatinum (II)) has been generated in vitro in the 41M human ovarian carcinoma cell line, established from a previously untreated patient. Three cisplatin-resistant variants were selected at approximately 2, 4 and 6-fold resistance (in terms of IC_{50} inhibitory concentrations), in order to study the underlying mechanisms of acquired cisplatin resistance. Compared to the parent line, platinum accumulation following exposure to equimolar concentrations of cisplatin was on average (across the entire concentration range) 2.9, 3.6 and 4.8-fold lower in the 41McisR2, 41McisR4 and 41McisR6 cell lines, respectively. Thus the differences in drug uptake were not due to a resistance factor in the three resistant variants. Moreover, a significant reduction in platinum accumulation was observed as early as 5 min after exposure to cisplatin in the 41 M vs 41McisR6 cell lines. Platinum accumulation was similar in all cell lines following exposure to equitoxic concentrations (2 B IC_{50}) of cisplatin. Enhanced efflux of drug was not observed between the 41M and 41McisR6 cells. In addition, there was no difference in intracellular glutathione (GSH) levels. Our previous studies have shown no indication of metallothionein involvement and the decrease in cisplatin uptake in the 41McisR6 cells was reflected by a similar reduction in DNA interstrand cross-links (ISC) formation. These results suggest that the mechanism of acquired resistance to cisplatin in the 41McisR6 cell line may be predominantly due to reduced drug uptake. The 41McisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of sodium-potassium-ATPase (Na*, K*-ATPase), suggesting that decreased cisplatin accumulation in these cells is probably not regulated by alterations in their Na*, K*-ATPase levels, and Na* potential across the plasma membrane. Cellular accumulation of a novel class of platinum (IV) ammine/cyclohexasmine dicharboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to cisplatin in the 41McisR line, was also examined. The data suggests that increased accumulation of these compounds, as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency over cisplatin.

Cisplatin is a widely used anticancer drug, particularly in the treatment of human ovarian, testicular, bladder, and head and neck cancers (Loehrer & Einhorn, 1984; Ozols & Young, 1984; Calvert et al., 1985). However, the emergence of drug resistance in the tumour cells and the unfavourable toxicity profile of cisplatin (primarily nephrotoxicity) still reduces its efficacy (Ozols & Young, 1984; Hromas et al., 1987). The second generation drug, carboplatin, although devoid of the major toxic limitations of the parent drug (Harrap, 1985), has a similar spectrum of antitumour activity. Hence, there is an urgent need for developing platinum drugs which are capable of circumventing cisplatin/carboplatin resistance.

Many studies have reported several potential biochemical mechanisms of cisplatin resistance. They have focused on descriptions of cross-resistance, differences in intracellular detoxification, decreased chromatin binding, reduced DNA damage and enhanced DNA repair mechanisms, and reduced drug accumulation, typically between established pairs of sensitive and acquired cisplatin-resistance variant cell lines (for reviews see Richon & Eastman, 1986; De Graeff et al., 1988; Andress & Howell, 1990).

A positive correlation has been observed between cisplatin cytotoxicity and accumulation in tumour cells (Eichholtz-Wirth & Hietel, 1986; Metcalfe et al., 1986). Many studies have implicated a platinum accumulation defect as an important mechanism of cisplatin resistance in both murine (Hromas et al., 1987; Kraker & Moore, 1988) and human carcinoma cell lines (Teicher et al., 1987; Andrews et al., 1988; Mann et al., 1990). Moreover, this may occur at an early stage during development of cisplatin resistance (Andrews et al., 1988; Andrews & Howell, 1990; Andrews et al., 1990). It should be noted, however, that some cell lines with cisplatin resistance do not show any difference in accumulation (e.g., GLC-CDDP human small cell lung Hospers et al., 1988). The exact mechanism of cisplatin transport into cells is unknown. It has been postulated that cisplatin enters cells by passive diffusion. However, studies have shown that cisplatin accumulation can be modulated by various treatments which suggests that transport mechanisms other than simple passive diffusion may be involved (Andrews & Howell, 1990).

Cellular resistance may either be present at the onset of treatment (intrinsic) or develop after an initial response (acquired). Our platinum-based drug discovery program, is aimed at developing a new generation of platinum analogues, capable of circumventing both intrinsic and acquired resistance to cisplatin and to broaden its clinical spectrum of activity. To assist in these objectives, we are establishing in vitro and in vivo screening models exhibiting intrinsic and acquired resistance to cisplatin, and determining mechanisms of resistance in these models. We have selected a sensitive human ovarian carcinoma cell line, 41M, which was established from a previously untreated patient, and developed sublines with varying degrees of resistance to cisplatin. We have examined differences in cisplatin accumulation, drug efflux, and GSH levels in these cell lines. As two previous reports have suggested a role for the membrane-bound Na*, K*-ATPase in cisplatin uptake (Kawai et al., 1987; Andrews et al., 1991) we determined the cytotoxicity of ouabain, a postulated specific inhibitor of the Na*, K*-ATPase, in these cell lines. In addition, the cytotoxicity of a novel class of platinum (IV) ammine/cyclohexasmine dicharboxylates and a Pt (II) complex, JMI18 (cis-aminedichloro (cyclohexasmine) platinum (II)), which exhibit dramatic and selective cytotoxic activity in cisplatin-refractory cell lines (Harrap et al., 1991; Kelland et al., 1992a), has been determined. The accumulation of these complexes in the sensitive and resistant cell lines was also compared with that of cisplatin.

Correspondence: S. Loh, Drug Development Section, The Institute of Cancer Research, Block E, 15, Cotswold Road, Bensoni, Sutton, Surrey SM2 5NG, UK.

Received 3 June 1992; and in revised form 17 July 1992.
Materials and methods

Drugs and chemicals

All platinum-containing agents were synthesized by and obtained from the Johnson Matthey Technology Centre (Reading, Berkshire, UK). The procedures for the synthesis of these drugs have been described recently (Giandomenico et al., 1991). The structures of the platinum complexes and the generalised structure of platinum (IV) ammine/cyclohexylamine dicarboxylates used in this study are shown in Figure 1. Ouabain octahydrate and all other chemicals were purchased from Sigma Chemicals UK Ltd.

Cell lines

The human ovarian carcinoma cell line, 41M, used in this study was derived from a previously untreated patient. Details of its biological properties have been described previously (Hills et al., 1989). This cell line was made resistant to cisplatin by continuously exposing cells to increasing concentrations of drug (up to a maximum of 1 μM) over a 15-month period. Cell lines (41McisR2, 41McisR4, 41McisR5) with approximately 2-fold, 4-fold and 6-fold degrees of resistance respectively, were generated. Cells were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM) augmented to contain 10% fetal calf serum (Imperial Laboratories, Andover, UK), 50 μg ml⁻¹ gentamicin, 2.5 μg ml⁻¹ amphotericin B, 2 mM L-glutamine, 10 μg ml⁻¹ insulin, and 0.5 μg ml⁻¹ hydrocortisone in a 10% CO₂, 90% air atmosphere. Cells were periodically checked and were found to be free of mycoplasma.

Assessment of cytotoxicity

All platinum agents were dissolved immediately before use in either 0.9% saline (at 500 μg for cisplatin, JM118, and JM216) or absolute ethanol (at 5 mM for the other platinum (IV) dicarboxylates). The final concentration of platinum (0.5%) in the medium had no growth-inhibitory effect on the cells. Ouabain was dissolved in sterile water at 1 mM.

Cytotoxicity was assessed as described recently (Mistry et al., 1991; Kelland et al., 1992a) using the sulforhodamine B (SRB) assay. Briefly, single viable cells were seeded into 96-well microtitre plates (1 x 10⁴ cells/well in 200 μl of growth medium). After an overnight attachment period, cells in quadruplicate wells were exposed to various concentrations of agents for either 2 or 96 h. After a 2 h exposure period, the cells were consecutively washed with 200 μl of phosphate buffered saline, pH 7.2 (PBS) and medium at 37°C. Fresh medium was then added to the cells and the plates were further incubated for 96 h. Basic amino acid content/well was analysed using 0.4% SRB in 1% acetic acid.

Intracellular platinum accumulation

Platinum drugs were added to approximately 1 - 4 x 10⁶ exponentially growing cells either at various concentrations for 2 h or at a single concentration for various times up to 120 min. Immediately after the drug exposure period, the medium was aspirated and the cells were washed with 3 x 25 ml of ice-cold PBS. Subsequently, the cells were scraped, harvested in 0.5 ml PBS and sonicated (Soniprep 150, Fisons, Loughborough, UK) at 4°C. The intracellular platinum content was determined using flameless atomic absorption spectrometry (Perkin Elmer 1100B and HGA 700, Beaconsfield, UK). Under these conditions the detection limit was 5 - 10 ng platinum per ml. Recovery was approximately 90%. Protein content was assayed according to Lowry et al. (1951) using a 50 μl aliquot of cell sonicate which had been digested overnight in 200 μl of 1.0 N sodium hydroxide at 37°C. Cellular platinum levels were expressed as nmol of platinum/mg of protein.

Drug efflux studies

The loss of cellular platinum over a 2 h period was examined after preincubating the 41M and 41McisR6 cells (1 - 4 x 10⁶) with 50 and 200 μM cisplatin, respectively for 30 min. At these incubation concentrations, cellular platinum levels at 30 min were similar in the two cell lines. In another set of experiments, parent and resistant variant were preincubated for 120 min in 50 μM cisplatin. At the end of the drug-loading period, the medium was aspirated and the monolayers were washed with 2 x 8 ml of drug-free medium. The washing procedure time of 90 s was added on to the efflux time. Cells were then incubated further in fresh medium for various times up to 120 min. Efflux was terminated by aspirating the medium and washing the cells with 3 x 25 ml ice-cold PBS. Cells were then processed and analysed for platinum and protein as described above.

GSH assay

The total GSH content of the cell lines were determined by an enzymatic assay utilising glutathione reductase as described recently (Mistry et al., 1991). The GSH content was expressed as nmol per 10⁶ cells or per mg protein.

Statistical analysis

All statistical analysis was performed using the Student's t-test.

Results

Although none of the lines have been cloned, the acquired resistant cell lines appeared identical to the parent line in terms of morphology under phase-contrast microscopy and the population doubling time (27 h). The parent line had been passaged in vitro around 30 times before the generation of resistance was begun. As described previously (Hills et al., 1989) 41M cells appeared as homogeneous small round cells within tightly adherent colonies. In addition, there were no significant differences in cell volume which was determined using a coulter counter.

Cytotoxicity of platinum complexes

The three cisplatin-resistant variants of the 41M cell line used in the accumulation studies were selected at approximately 2, 4, and 6-fold resistant, as determined by the SRB assay, after a 96 h continuous drug exposure. The resistance factors after
2 h drug exposure were slightly lower (Table I). Resistance appeared to be stable for at least 6 months without further maintenance doses of cisplatin. The sensitivity profile of 41M and 41McisR6 cells to four novel platinum (IV) ammine/cyclohexylamine dicarboxylates and to a platinum (II) complex (JM118) after a 2 and 96 h continuous exposure, is shown in Table II. The four platinum (IV) compounds had varying numbers of total carbon atoms (4–20) in their axial chains; JM216 (R = CH3), JM221 (R = nC3H7), JM274 (R = C4H9), and JM280 (R = nC6H13). Enhanced cytotoxicity of these platinum (IV) complexes was observed as the number of axial carbon atoms increased from four to ten. The compound containing the longest axial chain, JM280 (with 20-carbon atoms), however, retained an IC50 similar to the 10-carbon complex, JM274. This study correlated with our previous findings in six human ovarian carcinoma cell lines (Kelland et al., 1992a). The cross-resistance profile of 41-McIsR6 vs the parent line of these platinum (IV) agents is shown in Figure 2. The dicarboxylate compounds were able to circumvent completely resistance to cisplatin in the 41-McIsR6 cell line (resistance factor < 1.5).

Cytotoxicity of ouabain

The IC50 for ouabain after a 96 h continuous drug exposure was 0.084 and 0.043 (mean; n = 2) in the 41M and 41McisR6 cell lines, respectively. Hence, the cisplatin acquired-resistant cell line, 41McisR6, which was approximately 6-fold resistant to cisplatin, was not cross-resistant to ouabain (resistance factor = 0.6).

Cisplatin accumulation

To examine whether the basis for the acquired resistance to cisplatin was related to alterations in drug accumulation, we have determined the intracellular platinum levels immediately after a 2 h exposure to various concentrations of cisplatin. Although the maximum concentration of drug was higher than the IC50 concentrations (2 h exposure) we did not observe any cellular detachment during the washing procedure and, moreover, similar levels of protein were obtained to that at lower cisplatin concentrations. Figure 3 shows that platinum accumulation in the parent and three acquired-resistant variants was a linear function of cisplatin concentration up to at least 100 μM. In fact, lack of saturation of platinum accumulation was observed up to 500 μM cisplatin concentration in all cell lines (data not shown). At each exposure concentration, platinum levels were reduced significantly (P = 0.01) in the acquired-resistant variants when compared with the parent line. However, there was no significant difference at any cisplatin concentration in platinum levels between the 2- and 4-fold resistant lines. Across the range of concentrations used, intracellular platinum levels when compared to the parent line, were an average (across the entire concentration range) of 2.9 ± 0.6, 3.6 ± 1.0, and 4.8 ± 0.6-fold lower in the 41McIsR2, 41McIsR4, and 41McIsR6 variants, respectively. Hence, the -fold reduction (calculated only for the 25 μM dose-point) in platinum accumulation was similar to the resistance factor in each cell line (Table I). In contrast, the intracellular platinum levels after exposure to equitoxic concentrations of cisplatin were found to be similar for all cell lines (Table I).

Figure 4 shows that following exposure to 100 μM cisplatin, platinum accumulation was linear over 60 min (r = 0.982) for 41M and over 120 min (r = 0.992) for 41McIsR6. Additionallly, a significant reduction in accumulation in the acquired-resistant variant was observed at the earliest time point of 5 min. The reduction ranged from 1.5–2.5-fold over the 120 min exposure period and was statistically significant at all times (P < 0.01).

The time course for platinum efflux into drug-free medium was determined in 41M and 41McIsR6 cell lines following a 30 min loading period at 50 and 200 μM cisplatin (Figure 5a) and 120 min at 50 μM cisplatin (Figure 5b). No significant difference in efflux of platinum was observed between the cell lines (P > 0.5 at each time point investigated). The amount of platinum which escaped from both cell lines (20–30%) was independent of whether the cells were loaded with 50 or 200 μM cisplatin, or whether the cells were loaded for 30 or 120 min.

Accumulation of novel platinum (IV) complexes

To determine if enhanced cellular accumulation contributed to the lack of cross-resistance of platinum (II and IV) com-

Table I Relationship between cytotoxicity and cisplatin accumulation in sensitive parent and cisplatin-acquired-resistant variants

| Cell line   | 2 h IC50 (μM) | RF | 2 h IC50× | Pt accumulation (pmol Pt/mg protein) |
|-------------|---------------|----|-----------|-------------------------------------|
| 41M         | 3.0 ± 0.9     | –  | 30        | 278(1.0)                            |
| 41McIsR2    | 7.3 ± 2.6     | 2  | 29        | 85(3.2)                             |
| 41McIsR4    | 8.8 ± 0.3     | 2  | 23        | 70(4.0)                             |
| 41McIsR6    | 9.2 ± 3.3     | 3  | 32        | 50(5.6)                             |

RF = resistance factor (IC50 cisR/IC50 parent). *Values were obtained from accumulation curves (Figure 3). Values represent mean of three determinations. Numbers in parentheses represent -fold reduction in platinum accumulation relative to the parent line.

Table II In vitro sensitivity profile of 41M and 41McisR6 cells after 2 and 96 h exposure to platinum drugs

| Platinum drug | R   | 2 h IC50 (μM)  | 96 h IC50 (μM) |
|---------------|-----|---------------|----------------|
|               |     | 41M           | 41McisR6       | 41M           | 41McisR6       |
| Cisplatin     | –   | 2.9 ± 0.8     | 8.5 ± 0.1      | 0.2 ± 0.01    | 1.3 ± 0.07    |
| JM118         | –   | 2.4 ± 0.5     | 1.1 ± 0.5      | 0.2 ± 0.02    | 0.1 ± 0.01    |
| JM216         | nC3H7| 19 ± 6.4      | 13.5 ± 2.1     | 0.8 ± 0.06    | 0.4 ± 0.05    |
| JM221         | nC3H7| 12 ± 0.4      | 12 ± 0.4       | 0.8 ± 0.03    | 0.2 ± 0.02    |
| JM224         | nC6H13| 0.8 ± 0.2     | 0.4 ± 0.2      | 0.1 ± 0.02    | 0.005         |
| JM280         | nC6H13| 1.1 ± 0.5     | 0.6 ± 0.3      | 0.01          | 0.011         |

Values = mean ± s.d. in 3 experiments.
pounds to cisplatin, we have compared their accumulation with that of cisplatin in the 41M (Figure 6a) and 41McisR6 (Figure 6b) cell lines. The accumulation of all 5 platinum compounds was significantly greater than that of cisplatin at equimolar concentrations in the 41McisR6 cell line. Moreover, there was no significant difference in the accumulation of these compounds between the parent and cisplatin acquired-resistant cell lines. Intracellular platinum accumulation in both cell lines was linear up to 25 \( \mu \text{M} \) for JM221 (\( R = n\text{C}_3\text{H}_7 \)), JM274 (\( R = n\text{C}_4\text{H}_9 \)) and JM280 (\( R = n\text{C}_9\text{H}_{11} \)), and up to 100 \( \mu \text{M} \) for cisplatin, JM118 and JM216 (\( R = \text{CH}_3 \)). In addition, a positive correlation between platinum accumulation and the number of axial carbon atoms (up to a total of 10) was observed at all drug concentrations in both cell lines. However, platinum accumulation following exposure to JM280 with 20 axial carbon atoms was similar to that of JM118 and JM216 (with 0 and 4 axial carbon atoms, respectively).

**Figure 3** Intracellular platinum accumulation immediately after a 2 h exposure to various concentrations of cisplatin in 41M (\( \bullet \)), 41McisR2 (\( \bigcirc \)), 41McisR4 (\( \blacksquare \)), and 41McisR6 (\( \triangle \)) cell lines. Error bars = \( \pm \) s.d. of triplicate determinations of 3–4 experiments. s.d. was less than the symbol size where not indicated.

**Figure 4** Intracellular platinum accumulation after various exposure times to cisplatin in 41M (\( \bullet \)) and 41McisR6 (\( \Delta \)) cell lines. Error bars = \( \pm \) s.d. of triplicate determinations in two experiments. s.d. was less than the symbol size where not indicated.
cysplatin, concentrations the toonto several-fold sulation present the resistance important have shown both that. Discussion significant reported levels showing that reduced drug accumulation may play a major role in the mechanism of acquired resistance to cisplatin in these cell lines. The reduced drug accumulation appears to be caused by reduced uptake and not increased efflux since no significant differences in the loss of platinum was observed between the 41M and 41McisR6 cell lines. These results correspond to the findings of Teicher et al. (1987) and Waud (1987). In contrast, Mann et al. (1990) reported that the rate constant for rapid efflux (within the first 5 min after a 10 min drug loading period) was 53% higher in resistant compared to parent 2008 human ovarian carcinoma cells.

The precise mechanism(s) by which cisplatin enters cells is unknown and both passive diffusion and carrier mediated transport have been implicated (for review see Andrews & Howell, 1990). We found that cisplatin accumulation was not saturable up to 500 μM which agrees with other studies in a variety of tissue types (Eichholz-Wirth & Hietel, 1986; Hequet et al., 1986; Hromas et al., 1987; Andrews et al., 1988). Although this suggests that transport of cisplatin may occur

---

**Table III GSH levels in 41M and cisplatin acquired resistant variants**

| Cell line | GSH concentration (nmol/10^6 cells/mg protein) |
|-----------|-----------------------------------------------|
| 41M       | 18.2 ± 3.3                                    |
| 41McisR2  | 12.5 ± 4.8                                    |
| 41McisR4  | 27.2 ± 14.3                                   |
| 41McisR6  | 21.8 ± 9.7                                    |

Values = mean ± s.d. of duplicate determinations in 3–4 experiments.

---

**GSH concentrations**

Intracellular GSH was measured to determine if elevated levels contributed to the resistant phenotype as has been reported elsewhere (Arrick & Nathan, 1984; Green et al., 1984; Andrews et al., 1985; Louie et al., 1985). There was no significant difference (P > 0.05) in GSH concentration between parent and acquired-resistant variants, in terms of either cell numbers or protein content (Table III).

---

**Discussion**

Both intrinsic and acquired resistance to cisplatin limit the clinical utility of this valuable anticancer drug. Many studies have shown that decreased accumulation of cisplatin is an important factor in the in vitro and in vivo acquisition of resistance to this antitumour compound (Hromas et al., 1986; Richon & Eastman, 1986; Richon et al., 1987; Teicher et al., 1987; Kraker & Moore, 1988; Andrews et al., 1990). In the present study we examined the role of reduced drug accumulation as a possible mechanism of resistance to cisplatin in the acquired-resistant variants of a sensitive human ovarian carcinoma cell line (41M), which was established from a previously untreated patient. Intracellular platinum accumulation was significantly reduced in the acquired-resistant variants compared to the parent line. Furthermore, the several-fold reductions following exposure to equimolar concentrations of cisplatin closely paralleled the resistance factors to cisplatin. However, at equitoxic concentrations of cisplatin, similar amounts of platinum were accumulated in the parent and the resistant sublines. These results suggest
primarily by passive diffusion, the involvement of carrier
mediated transport cannot be ruled out. Several reports have
shown that cisplatin accumulation can be modulated by
various treatments (e.g., Kikuchi et al., 1990; Morikage et al.,
1991). In addition, specific changes in plasma membrane
proteins have been reported in association with reduced cis-
platin accumulation in resistant cells (Bernal et al., 1990;
Kawai et al., 1990). We are currently evaluating whether
alterations in cell membranes are responsible for the reduced
drug uptake in the acquired resistant 41McisR6 cell line.
Recently both Kawai et al. (1987) and Andrews et al. (1991)
have postulated a central role for Na⁺,K⁺-ATPase in cis-
platin accumulation. This enzyme regulates the transmem-
brane Na⁺ gradients which in turn was found to partially
regulate cisplatin accumulation in the 2008 human ovarian
cell line (Andrews et al., 1991). However, our results showed
a lack of cross-resistance to ouabain, a postulated specific
inhibitor of Na⁺,K⁺-ATPase, in the 41McisR6 cell line. This
suggests that reduced drug accumulation in these cells is
probably not regulated by an alteration in their Na⁺,K⁺-
ATPase levels.

Ammonia/ammine platinum (IV) dicarboxylates represent a
novel class of antitumour complex which exhibit selective
activity in cisplatin-refractory cell lines (Harrap et al., 1991;
Kelland et al., 1992a). Some of these dicarboxylates, es-
pecially those containing a total of 8 or more carbon atoms
in their axial ligands, possess dramatic in vitro cytotoxic
properties against human carcinoma lines (Kelland et al.,
1992a). Therefore, these compounds may provide a lead to
the development of platinum drugs capable of circumvent-
ing cisplatin resistance. In this study we have compared the
cytotoxicity of cisplatin with that of a platinum (II) complex
(JM118) and 4 platinum (IV) ammine/cyclohexylamine dicar-
boxylates in the 41M and 41McisR6 cell lines. The dicarboxy-
late complexes examined contained a range of 4–20 total
number of axial carbon atoms. Interestingly, all these com-
plexes (including JM118) were capable of circumventing ac-
quired resistance to cisplatin in the 41McisR6 cell line and
some were more potent than cisplatin in the parent cell line.
To establish the mechanistic basis for their increased potency
and lack of cross-resistance to cisplatin, we have compared
the accumulation of these complexes with that of cisplatin in
the sensitive and resistant cells. Our results indicated that the
lack of cisplatin resistance may be attributable to the fact that
the resistant cells were unable to retard the accumulation of
these complexes. This may be related to their increased lipo-
philicity since accumulation of these dicarboxylates increased
with increasing number of axial carbon atoms up to a total of
10. For example, while solubility in water (at 25°C)
decreased along the series cisplatin (1183 μg mL⁻¹), JM118
(216 μg mL⁻¹), JM216 (170 μg mL⁻¹), and JM221 (75 μg mL⁻¹),
solubility in octanol increased from 7.8 μg mL⁻¹ for cisplatin,
to values of 37 for JM118, 54 for JM216, and 1317 for JM221.
However, JM280, one of the most potent compounds with
20 axial carbon atoms, showed similar levels of accu-
mulation to JM216, which contained only 4 axial carbon
atoms.

Other factors involved in the mechanism of resistance such
as intracellular detoxification through interaction with cellu-
lar thiols, or reduced Pt-DNA adduct formation and
enhanced repair of DNA lesions must also be taken into
account. Differences in GSH levels between sensitive and
resistant cells cannot be implicated here, since none were
found (Table III). Whether reduced GSH contributes the
acquired-resistant phenotype appears to be dependent upon
cell type since some show differences between sensitive and
resistant lines (e.g. Green et al., 1984; Louie et al., 1985) and
others do not (e.g. Andrews et al., 1985). We have reported
previously that there was no direct involvement of intracel-
lar metallothioneins in the mechanism of resistance, as
indicated by the sensitivity of the cell lines to cadmium
chloride (Loh et al., 1991). Furthermore, the reduction in cis-
platin uptake in 41McisR6 cells was reflected by a similar
reduction in DNA interstrand crosslink formation, as mea-
sured by alkaline filter elution (Loh et al., 1991; Kelland et
al., 1992b).

In summary, reduced drug accumulation plays a major
role in the mechanism of cisplatin acquired-resistance in the
41McisR6 cell line. Moreover, since reduced drug accumula-
tion was observed in ancestors of this cell line with lower
levels of resistance, it appears that this mechanism is involved
at an early stage in the development of cisplatin resistance
in these cells. Identification of alterations in plasma membranes
of these cells could provide new strategies to circumvent
cisplatin resistance caused by reduced drug accumulation.
We have also shown, through use of the novel platinum (IV)
ammine/cyclohexylamine dicarboxylate complexes, that resis-
tance to cisplatin caused by reduced drug accumulation may
be largely overcome by increasing the lipophilicity of the
platinum agent. Such compounds could provide a lead to
new ‘third-generation’ platinum containing agents to combat
cancers currently resistant to cisplatin and which might
exhibit a broader spectrum of antitumour activity.

This work was supported by grants to the Institute of Cancer
Research from the Cancer Research Campaign (UK). the Medical
Research Council, the Johnson Matthey Technology Centre and
Bristol Myers Squibb Oncology. We also thank Dr Barry Murrer
(Johnson Matthey Technology Centre Reading, Berkshire, UK),
for solubility data and helpful comments.

References
ANDREWS, P.A., MURPHY, M.P. & HOWELL, S.B. (1985). Differential
potentiation of alkylating and plating agents cytotoxicity
in human ovarian carcinoma cells by glutathione depletion. Cancer Res.,
45, 6250–6253.

ANDREWS, P.A., VELURY, S., MANN, S.C. & HOWELL, S.B. (1988).
Cis-diaminedichloroplatinum(II) accumulation in sensitive and
resistant human ovarian carcinoma cells. Cancer Res., 48, 68–73.

ANDREWS, P.A. & HOWELL, S.B. (1990). Cellular pharmacology of cisplatin:
perspectives on mechanisms of acquired resistance.
Cancer Cells, 2, 35–43.

ANDREWS, P.A. & JONES, J.A., VARKI, N.M. & HOWELL, S.B. (1990).
Rapid emergence of acquired cis-diaminedichloroplatinum (II)
resistance in an in vitro model of human ovarian carcinoma.
Cancer Commun., 2, 93–100.

ANDREWS, P.A., MANN, S.C., HUYNH, H.H. & ALBRIGHT, K.D.
(1991). Role of the Na⁺,K⁺-Adenosine Triphosphatase in the
accumulation of cis-diaminedichloroplatinum (II) in human
ovarian carcinoma cells. Cancer Res., 51, 3677–3681.

ARRICK, B.A. & NATHAN, C.F. (1994). Glutathione metabolism as a
determinant of therapeutic efficacy: a review. Cancer Res., 44,
4224–4232.

BERNAL, S.D., SPEAK, J.A., BOEHEIM, K., DREYFUSS, A.I., WRIGHT,
J.E., TEICHER, B.A., ROSOWSKY, A., TSAO, S.W. & WONG, Y.C.
(1990). Reduced membrane protein associated with resistance of
human squamous carcinoma cells to methotrexate and cis-platin.
Mol. Cell. Biochem., 95, 61–70.

CALVERT, A.H., HAMLAND, S.T., NEWELL, D.R., SIDDIK, Z.H.
& HARRAP, K.R. (1985). Phase I studies with carboplatin at the
Royal Marsden Hospital. Cancer Treat Rev., 12 (Suppl A), 51–57.

DE GRAEFF, A., SLEBS, R.J.C. & RODENHUIS, S. (1988). Resistance to
cisplatin and analogues: mechanisms and potential clinical
implications. Cancer Chemother. Pharmacol., 22, 325–332.

EICHHOLTZ-WERTH, H. & HIETEL, B. (1986). The relationship
between cisplatin sensitivity and drug uptake into mammalian cells
in vitro. Br. J. Cancer, 54, 239–243.

GIANDOMENICO, C.M., ABRAMS, M.J., MURRER, B.A., VOLLANO,
J.F., HARRAP, K.R., GODDARD, P.M., KELLAND, L.R. & MOR-
GAN, S.E. (1991). Synthesis and reactions of a new class of orally
active (Pt(IV) antitumour complexes. In Howell, S.B., (ed.)
Platinum and Other Metal Coordination Complexes in Cancer
Chemotherapy, Plenum Press: New York, pp. 93–100.
GREEN, J.A., VISTICA, D.T., YOUNG, R.C., HAMILTON, T.C., RAGON, A.M. & OZOLS, R.F. (1984). Potentiation of mephalan cytotoxicity in human ovarian cancer cells by glutathione depletion. Cancer Res., 44, 5427–5431.

HARRAP, K.R. (1985). Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev., 12 (Suppl. A), 21–32.

HARRAP, K.R., MURRER, B.A., GIANDOMENICO, C., MORGAN, S.E., KELLAND, L.R., JONES, M., GODDARD, P.M. & SCHURIG, J. (1991). Ammine/ammine platinum IV dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance. In Howell, S.B. (ed.) Platinum and other Metal Coordination Compounds Cancer Chemotherapy, Plenum Press: New York, pp. 391–399.

HECUET, B., LEROY, A., LEEFEBVRE, J.L., PEYRAT, J.P. & ADENIS, L. (1986). Uptake of platinum compounds in human tumours. In vitro study. Bull Cancer, 73, 535–541.

HILLS, C.A., KELLAND, L.R., ABEL, G., SIRACKY, J., WILSON, A.P. & HARRAP, K.R. (1989). Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59, 527–534.

HOPERS, G.A., MULDER, N.H., DE JONG, B., DE LEY, L., UGES, D.R.A., FICTHINGER-SCHEPER, A.M., SCHEPER, R.J. & DE VRIES, E.G.E. (1988). Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-Diammine dichloroplatinum(II) in vitro. Cancer Res., 48, 6803–6807.

HUMANS, R.H., NOH, H.J. & BURNS, C.P. (1987). Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett., 33, 197–201.

KAWAI, K., KATANAMI, N., KUROSHINA, S., NOBORI, T., NISHIOKA, K., KAMIYA, H., SAKURAI, M. & MIKANAGI, K. (1987). Cross-resistance to ouabain in a murine leukemia cell variant selected for cis-dichlorodiammineplatinum(II) resistance. Cancer Lett., 35, 147–152.

KAWAI, K.K., GEORGES, E. & LING, V. (1990). Identification of membrane glycoprotein overexpressed in murine lymphoma resistance to cis-diaminedichloroplatinum(II). J. Biol. Chem., 265, 13137–13142.

KELLAND, L.R., MURRER, B.A., ABEL, G., GIANDOMENICO, C.M., MISTRY, P. & HARRAP, K.R. (1992a). Ammine/ammine platinum IV dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 52, 822–828.

KELLAND, L.R., MISTRY, P., ABEL, G., LOH, S.Y., O’NEILL, C.F., MURRER, B.A. & HARRAP, K.R. (1992b). Mechanism-related circumvention of acquired cis-Diaminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/ammine platinum (IV) dicarboxylates. Cancer Res., 52, 3857–3864.

KIKUCHI, Y., IWANO, I., MIYAUCHI, M., SASA, H., NAGATA, I. & KUKI, E. (1990). Restorative effects of calmodulin antagonists in reduced cisplatin uptake by cisplatin-resistant human ovarian cancer cells. Gynecol. Oncol., 39, 199–203.

KRAKER, A.J. & MOORE, C.W. (1988). Accumulation of cis-diaminedichloroplatinum (II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res., 48, 9–13.

LOEHRER, P.J. & EINHORN, L.H. (1984). Cisplatin. Ann. Int. Med., 100, 704–713.

LOH, S.Y., MISTRY, P., KELLAND, L.R., ABEL, G. & HARRAP, K.R. (1991). A comparison of resistance mechanisms in two cisplatin acquired resistant human ovarian carcinoma cell lines. Br. J. Cancer, 63, 40 (Abst).

LOUIE, K.G., BEHRENS, B.C., KIRSSELL, T.J., HAMILTON, T.C., GROTTINGER, K.R., MCKÖY, W.M., WINKER, M.A. & OZOLS, R.E. (1985). Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res., 45, 2110–2115.

LOWRY, O.H., ROSEBROUGH, M.T., FARR, A.L. & RANDALL, R.J. (1951). Protein measurements with the folin phenol reagent. J. Biol. Chem., 193, 265–275.

MANN, S.C., ANDREWS, P.A. & HOWELL, S.B. (1990). Short-term cis-diaminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 25, 236–240.

METCALFE, S.A., CAIN, K. & HILL, B.T. (1986). Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett., 31, 163–169.

MISTRY, P., KELLAND, L.R., ABEL, G., SIDHAR, S. & HARRAP, K.R. (1991). The relationship between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64, 215–220.

MORIKAGE, T., BUNGO, M., INOMATA, M., YOSHIDA, M., OHIHORI, T., FUJWARA, Y., NISHIO, K. & SAJO, N. (1991). Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn. J. Cancer Res., 82, 747–751.

OZOLS, R.F. & YOUNG, R.C. (1984). Chemotherapy of ovarian cancer. Semin. Oncol., 11, 251–263.

RICHDON, V.M. & EASTMAN, A. (1986). Mechanisms of cellular resistance to platinum coordination complexes. In McBrien, D.C.H. & Slater, T.F. (eds) Biochemical Mechanisms of Platinum Anti-tumour Drugs, IRL Press Ltd: Oxford, pp. 91–119.

RICHDON, V.M., SCHULTZE, N. & EASTMAN, A. (1987). Multiple mechanisms of resistance to cis-diaminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res., 47, 2056–2061.

TEICHER, B.A., HOLDEN, S.A., KELLY, M.J., SHEA, T.C., CUCCHI, C.A., ROSOWSKY, A., HENNTER, W.D. & FREI, E. III (1987). Characterisation of a human squamous carcinoma cell line resistant to cis-diaminedichloroplatinum (II). Cancer Res., 47, 388–393.

WAUD, W.R. (1987). Differential uptake of cis-diaminedichloro platinum (II) by sensitive and resistant murine leukemia cell. Cancer Res., 47, 6549–6555.